Amphastar Pharmaceuticals, Inc.
AMPH
$28.87
$0.0550.19%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Revenue | 712.81M | 681.49M | 644.52M | 610.85M | 593.24M |
Total Other Revenue | 19.15M | 42.06M | 68.37M | 65.36M | 51.16M |
Total Revenue | 731.97M | 723.55M | 712.89M | 676.21M | 644.40M |
Cost of Revenue | 358.11M | 340.20M | 323.08M | 308.83M | 290.57M |
Gross Profit | 373.86M | 383.35M | 389.81M | 367.38M | 353.82M |
SG&A Expenses | 94.52M | 92.90M | 88.15M | 84.85M | 80.39M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 526.55M | 509.29M | 483.01M | 464.65M | 444.71M |
Operating Income | 205.42M | 214.26M | 229.89M | 211.56M | 199.69M |
Income Before Tax | 189.19M | 186.07M | 201.63M | 183.90M | 169.38M |
Income Tax Expenses | 29.67M | 28.35M | 35.12M | 29.21M | 31.83M |
Earnings from Continuing Operations | 159.52 | 157.72 | 166.52 | 154.69 | 137.55 |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | 159.52M | 157.72M | 166.52M | 154.69M | 137.55M |
EBIT | 205.42M | 214.26M | 229.89M | 211.56M | 199.69M |
EBITDA | 258.39M | 266.61M | 281.46M | 256.09M | 237.72M |
EPS Basic | 3.29 | 3.26 | 3.44 | 3.20 | 2.85 |
Normalized Basic EPS | 2.44 | 2.40 | 2.60 | 2.38 | 2.23 |
EPS Diluted | 3.06 | 3.01 | 3.14 | 2.90 | 2.59 |
Normalized Diluted EPS | 2.27 | 2.22 | 2.38 | 2.15 | 2.02 |
Average Basic Shares Outstanding | 193.72M | 193.70M | 193.78M | 193.27M | 193.06M |
Average Diluted Shares Outstanding | 208.23M | 209.94M | 211.99M | 213.05M | 212.01M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |